{"id":7220,"date":"2025-09-29T23:02:35","date_gmt":"2025-09-29T23:02:35","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/09\/29\/fda-george-tidmarsh-linkedin-aurinia\/"},"modified":"2025-09-29T23:02:35","modified_gmt":"2025-09-29T23:02:35","slug":"fda-george-tidmarsh-linkedin-aurinia","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/09\/29\/fda-george-tidmarsh-linkedin-aurinia\/","title":{"rendered":"STAT+: Top FDA drug regulator\u2019s unusual criticism of a therapy gets Wall Street wagging"},"content":{"rendered":"<p>    STAT+: Top FDA drug regulator\u2019s unusual criticism of a therapy gets Wall Street wagging<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>Is George Tidmarsh, the Food and Drug Administration\u2019s top regulator, trying to exact revenge on a prominent Wall Street investor after a run-in with him six years ago?\u00a0<\/p>\n<p>It\u2019s the question biotech investors were wagging about all Monday after Tidmarsh used his personal LinkedIn page to raise questions about the safety of voclosporin, a rather obscure drug the FDA approved in 2021 to treat patients with lupus nephritis, a type of autoimmune disease that damages the kidneys.\u00a0<\/p>\n<p>Voclosporin has \u201csignificant toxicity,\u201d Tidmarsh wrote in his LinkedIn post, adding that the drug \u201chas not been shown to provide a direct clinical benefit for patients.\u201d\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/09\/29\/fda-george-tidmarsh-linkedin-aurinia\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/09\/29\/fda-george-tidmarsh-linkedin-aurinia\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Top FDA drug regulator\u2019s unusual criticism of a therapy gets Wall Street wagging Is George Tidmarsh, the Food and Drug Administration\u2019s top regulator, trying to exact revenge on a prominent Wall Street investor after a run-in with him six years ago?\u00a0 It\u2019s the question biotech investors were wagging about all Monday after Tidmarsh used [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2200,2194,2154,2146,2176,2155,2152],"tags":[2150],"class_list":["post-7220","post","type-post","status-publish","format-standard","hentry","category-adams-take","category-biotech","category-biotechnology","category-fda","category-pharma","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7220"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=7220"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7220\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=7220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=7220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=7220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}